To Evaluate the Effectiveness of New Specially Designed Fitlens Soft Lens.
Launched by FITLENS LTD. · Jun 22, 2022
Trial Information
Current as of August 02, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of soft contact lens called Myolens, designed to help slow down the progression of myopia, or nearsightedness, in children aged 8 to 12. Myopia is a common vision problem that can lead to serious eye issues if it gets worse. The trial will compare two different Myolens designs to a currently approved treatment called MiSight. If your child joins the study, they’ll need to wear the Myolens for at least 10 hours a day, six days a week, over a three-year period.
To qualify for the trial, children must have normal eyesight, be willing to commit to regular visits, and meet specific eye health criteria. It's important that parents understand the study details and provide written consent before their child can participate. Throughout the trial, participants will be monitored closely, and their vision will be assessed to see how well the Myolens work in slowing myopia progression. Overall, this study aims to find a safe and effective way to help children manage their nearsightedness.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Be between 8 and 12 years of age inclusive at baseline examination.
- • 2. The participant has been given a detailed, clear explanation concerning the study aspects and procedures.
- • 3. The participant's parents or legal guardian have been given a clear explanation, then read, understood, and signed the informed consent form.
- • 4. Willingness to adhere to protocol, agreement to maintain the visit schedule.
- • 5. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study.
- • 6. Agreement to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the 3-year study.
- • 7. Subject with normal eyes who is not using any ocular medications.
- • 8. Possess wearable and visually functional eyeglasses.
- • 9. Be in good general health, based on his/her and parent's/guardian's knowledge.
- • 10. Best-corrected visual acuity by manifest refraction of +0.10 log MAR (20/25 or 6/7.5) or better in each eye. (Lens power required limited to up to minus 10).
- • 11. The manifest cylinder is less than or equal to 0,75D.
- 12. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline (per eye):
- • 1. Spherical equivalent refractive error: between -0.75 and -4.00 D inclusive.
- • 2. Astigmatism: ≤-0.75 D
- • 3. Anisometropia: \<1.00 D
- Exclusion Criteria:
- • 1. Subject is currently or within 30 days before this study has been an active participant in another clinical study involving an investigational treatment.
- • 2. Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine, or any other myopia control treatment.
- • 3. Birth earlier than 30 week or \<1500 g (3.3 lb) at birth.
- • 4. Regular use of ocular medications, artificial tears, or wetting agents.
- • 5. Current use of systemic medications, which may affect contact lens wear, tear film production, pupil size, accommodation, or refractive state.
- • 6. A known allergy to any of the Myolens components.
- • 7. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections, or other recurrent ocular infections.
- • 8. Strabismus by cover test at distance or near wearing distance correction.
- • 9. History of any of the following: ocular or systemic diseases, including those that could influence refractive development, anterior segment infection, inflammation or abnormality, any active anterior segment ocular disease that would contraindicate contact lens wear; history of herpetic keratitis; history of refractive surgery or irregular cornea (except when the contact lenses under investigation are indicated for irregular cornea, keratoconus or refractive surgery); a pathologically dry eye.
- • 10. Keratoconus or an irregular cornea (assessed by corneas topography)
- • 11. Contraindications for contact lens wear including giant papillary conjunctivitis of grade 2 or worse and allergic or seasonal conjunctivitis (assessed by slit lamp exam)
- • 12. Subject seems to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear) or the investigator for any reason considers that it is not in the best interest of the subject to participate in the study.
- • 13. Slit lamp findings that are more serious than grade 1 according to the Efron Grading Scale.
- • 14. Corneal vascularization greater than 1 mm of penetration
About Fitlens Ltd.
FitLens Ltd. is an innovative clinical trial sponsor dedicated to advancing healthcare through the development of cutting-edge medical technologies and solutions. With a focus on harnessing data analytics and wearable technology, FitLens Ltd. aims to improve patient outcomes and enhance clinical research methodologies. The company collaborates with healthcare professionals, researchers, and regulatory bodies to design and implement robust clinical trials that ensure the safety and efficacy of their products. Committed to transparency and ethical practices, FitLens Ltd. strives to contribute significantly to the medical community by delivering reliable evidence-based findings that drive informed decision-making in patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Holon, , Israel
Patients applied
Trial Officials
Nitza Cohen, MD
Principal Investigator
Bnei- Zion MC. Israel
Oriel Shpirer, MD
Principal Investigator
Wolfson MC. Israel
Shiri Shulman, MD
Principal Investigator
Assuta- Hashalom MC. Israel
José M González Méijome, MD
Principal Investigator
University of Minho- Portugal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials